Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep - Appendix 4E & 2022 Full Year Statutory Accounts (ASX:IMM)

CHAIRMAN’S LETTER Dear Fellow Shareholder: I’m delighted to present Immutep’s annual report for the financial year 2022. Immutep continued to forge its leadership role in the...read more

Immutep - Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1 (ASX:IMM)

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmu...read more

Immutep - TACTI-002 2nd line lung cancer data presented at 2022 WCLC (ASX:IMM)

-- Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC) -- Patients in this 2nd line setting had confirmed disease progression on anti...read more

Immutep - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:IMM)

-- Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activity -- Biomarker and ...read more

Notification of cessation of securities - IMM (ASX:IMM)

To view the Notification of cessation of +securities, download the attached PDF.

Immutep granted Japanese Patent for IMP761 (ASX:IMM)

SYDNEY, AUSTRALIA – 6 July 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy tre...read more

Immutep - TACTI-002 lung cancer data to be presented at 2022 WCLC (ASX:IMM)

SYDNEY, AUSTRALIA – 27 June 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related im...read more

Immutep Investor Update (ASX:IMM)

As the world’s biggest clinical cancer research conference, ASCO is always a very significant event on Immutep’s calendar. This year was extra special as we announced new and exciting cl...read more

Immutep - Webcast slides for 1st line NSCLC data from TACTI-002 trial (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - Positive ORR in 1st line NSCLC from ph 2 TACTI-002 trial (ASX:IMM)

* TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducted in collaboration with MSD (N=114) * Combina...read more

Immutep webcast for TACTI-002 data presented at ASCO 2022 (ASX:IMM)

SYDNEY, AUSTRALIA – 2 June 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related imm...read more

Immutep announces publication of ASCO 2022 abstracts (ASX:IMM)

* Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1st line non-small cell lung cancer (NSCLC) patients from TACTI-002 with data cut off January 2022 * Impr...read more

Immutep Corporate Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep to Present at Investor Conferences (ASX:IMM)

SYDNEY, AUSTRALIA – 20 May 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related imm...read more

Immutep - Leading Oncologists appointed to Clinical Advisory Board (ASX:IMM)

SYDNEY, AUSTRALIA – 18 May 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related imm...read more

Viewing: 166 - 180 of 200 Previous | Next